Logo for Boundless Bio Inc

Boundless Bio Investor Relations Material

Latest events

Logo for Boundless Bio

Q3 2024

7 Nov, 2024
Logo for Boundless Bio

Q2 2024

12 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Boundless Bio Inc

Access all reports
Boundless Bio Inc., trading under the NASDAQ symbol BOLD, is a clinical-stage oncology company focused on developing novel cancer treatments. The company leverages its proprietary Spyglass platform to target extrachromosomal DNA (ecDNA), which plays a significant role in oncogene amplification in over 14% of cancer patients. By identifying and inhibiting targets essential for ecDNA functionality, Boundless Bio aims to develop ecDNA-directed therapeutic candidates (ecDTx) designed to selectively eliminate cancer cells containing ecDNA without harming healthy cells. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.